131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma

Blood

Volumn 113, Issue 23, 2009, Pages 5905-5910

  Gopal, Ajay K ^a,b   Pagel, John M ^a,b   Fromm, Jonathan R ^c   Wilbur, Shani ^b   Press, Oliver W ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 30F11 I 125; MONOCLONAL ANTIBODY BC8 I 131; MONOCLONAL ANTIBODY BHV 1 I 125; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; T CELL LYMPHOMA; TUMOR LOCALIZATION; TUMOR XENOGRAFT; ANIMAL; DISEASE COURSE; DRUG SCREENING; IMMUNOLOGY; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD45; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, T-CELL; MICE; RADIOIMMUNOTHERAPY; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67651097893     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-205476     Document Type: Article

References (35)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non- Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16:2780-2795.
2. Rizvi MA, Evens AM, Tallman MS, Nelson BP, Rosen ST. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255-1264.
3. Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15: 1467-1475. (Pubitemid 39409735)
4. Vose JM. International Peripheral T-Cell Lymphoma (PTCL) Clinical and Pathologic Review Project: poor outcome by prognostic indices and lack of efficacy with anthracyclines [abstract]. Blood. 2005;106:811.
5. Vose JM. Update on T-cell lymphoma. Ann Oncol. 2008;19(suppl 4):74-76.
6. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled- antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
7. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441-449.
8. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) Bcell non-Hodgkin's lymphoma. J Clin Oncol. 1999;17:3793-3803.
9. Press OW, Unger JM, Braziel RM, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/ iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003;102:1606-1612.
10. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351-2357.
11. Jaffe ES, Blattner WA, Blayney DW, et al. The pathologic spectrum of adult T-cell leukemia/ lymphoma in the United States: human T-cell leukemia/ lymphoma virus-associated lymphoid malignancies. Am J Surg Pathol. 1984;8:263-275.
12. Nakano A, Harada T, Morikawa S, Kato Y. Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines. Acta Pathol Jpn. 1990;40:107-115. (Pubitemid 20283074)
13. Knowles DA, ed. Neoplastic Hematopathology, 2nd Ed. New York, NY: Lippincott Williams & Wilkins; 2001.
14. Poppema S, Lai R, Visser L, Yan XJ. CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Leuk Lymphoma. 1996;20: 217-222. (Pubitemid 3019022)
15. van der Jagt RH, Badger CC, Appelbaum FR, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res. 1992;52:89-94.
16. Pagel JM, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 2003;101:2340-2348. (Pubitemid 36302079)
17. Matthews DC, Martin PJ, Nourigat C, Appelbaum FR, Fisher DR, Bernstein ID. Marrow ablative and immunosuppressive effects of 131I-anti-CD45 antibody in congenic and H2-mismatched murine transplant models. Blood. 1999;93:737-745.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364-369.
20. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification-from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 2000;11(suppl 1):3-10. (Pubitemid 30111858)
21. Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol. 1994;47:313-317.
22. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920-2924. (Pubitemid 38451660)
23. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/ Sezary syndrome. Blood. 2003;101:4267-4272.
24. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19:376-388. (Pubitemid 32112849)
25. + hematologic malignancies. Blood. 2008; 111:1848-1854.
26. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90- labeled anti-Tac. Blood. 1995;86:4063-4075.
27. Foss FM, Raubitscheck A, Mulshine JL, et al. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma. Clin Cancer Res. 1998;4:2691-2700.
28. 131I- labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol. 1987;5:562-573.
29. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
30. Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59:1127-1137.
31. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol. 2006;134:202-207.
32. Rodriguez J, Caballero MD, Gutierrez A, et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy: the GEL-TAMO experience. Haematologica. 2003; 88:1372-1377. (Pubitemid 38029720)
33. Jantunen E, Wiklund T, Juvonen E, et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant. 2004;33:405-410.
34. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008;112:830-835.
35. 131Ianti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107:2184-2191.